BofA Securities Upgrades Y-mAbs Therapeutics (YMAB) to Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mail
Get Alerts YMAB Hot Sheet
Price: $8.61 --0%
Rating Summary:
5 Buy, 11 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Rating Summary:
5 Buy, 11 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Join SI Premium – FREE
BofA Securities analyst Alec Stranahan upgraded Y-mAbs Therapeutics (NASDAQ: YMAB) from Neutral to Buy with a price target of $56.00.
For an analyst ratings summary and ratings history on Y-mAbs Therapeutics click here. For more ratings news on Y-mAbs Therapeutics click here.
Shares of Y-mAbs Therapeutics closed at $28.65 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA Securities Upgrades Allegion (ALLE) to Buy
- RBC Capital Upgrades Sartorius AG (SRT3:GR) (SARTF) to Outperform
- UBS Upgrades Zurich Insurance Group AG (ZURN:SW) (ZURVY) to Neutral
Create E-mail Alert Related Categories
UpgradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
